“Reductions in Absolute PASI Over 144 Weeks of Treatment With Certolizumab Pegol in Patients With Plaque Psoriasis: Pooled Analysis from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2)”. SKIN The Journal of Cutaneous Medicine, vol. 4, no. 6, Oct. 2020, p. s84, https://doi.org/10.25251/skin.4.supp.84.